MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202641094674 A) filed by Dayananda Sagar University on August 05, 2026, for Novel Oral Formulation For Iron Deficiency With Enhanced Bioavailability.
Inventors include Amrutha C; Rashmi J; Sushma D. S; Manojkumar N I; Yashaswini H C; Sonali Bairagi; Sagarika Biswas; Sandipan Laha; Debjit Pahari; Sukamal Dash; and Dr. Santosh Kumar J.
The application for the patent was published on August 14, 2026, under issue no. 33/2026.
Abstract: The invention relates to a novel oral pharmaceutical formulation for the prevention and treatment of iron deficiency and iron-deficiency anemia with enhanced oral bioavailability and improved gastrointestinal tolerability. The formulation comprises a pharmaceutically acceptable iron source incorporated within a protected, complexed, chelated, microencapsulated, or lipid-polymer carrier system, together with one or more absorption-promoting agents. The protective system is configured to reduce premature oxidation, precipitation, and direct interaction of free iron with the gastric mucosa while maintaining the iron in a soluble or readily dispersible form. The formulation further incorporates an iron-solubilizing phase, optionally comprising ascorbate, citrate, amino acids, phospholipids, mucoadhesive polymers, or combinations thereof, and a release-controlling component configured to deliver iron preferentially to the duodenum and upper jejunum. The combined carrier and bioenhancer system increases dispersion, intestinal residence or mucosal contact, and availability of iron at the absorptive site. The composition may be manufactured as a tablet, capsule, granule, powder, sachet, suspension, or other pharmaceutically acceptable oral dosage form using complexation, emulsification, microencapsulation, granulation, coating, spray drying, or related processes. The invention provides a stable and scalable oral iron delivery platform intended to improve absorption at a lower or conventional elemental iron dose, reduce unabsorbed free iron exposure, and minimize commonly associated adverse effects such as nausea, abdominal discomfort, constipation, and metallic taste. The formulation is applicable to individuals with nutritional iron deficiency, iron-deficiency anemia, pregnancy-related iron deficiency, chronic blood loss, malabsorption-associated deficiency, and other conditions requiring oral iron supplementation.
Disclaimer: Curated by HT Syndication.
